TrialCPT: pharmacometrics & systems pharmacology2025

Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.

Jim H Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.